News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,010 Results
Type
Article (41591)
Company Profile (463)
Press Release (658956)
Section
Business (208392)
Career Advice (2002)
Deals (35941)
Drug Delivery (92)
Drug Development (83301)
Employer Resources (169)
FDA (16325)
Job Trends (15043)
News (352079)
Policy (32978)
Tag
Academia (2619)
Alliances (50599)
Alzheimer's disease (1273)
Approvals (16250)
Artificial intelligence (139)
Bankruptcy (361)
Best Places to Work (11732)
Biotechnology (349)
Breast cancer (123)
Cancer (1109)
Cardiovascular disease (102)
Career advice (1671)
Cell therapy (247)
Clinical research (65988)
Collaboration (404)
Compensation (199)
COVID-19 (2590)
C-suite (100)
Data (1136)
Diabetes (156)
Diagnostics (6196)
Earnings (86042)
Employer resources (147)
Events (112903)
Executive appointments (313)
FDA (16865)
Funding (362)
Gene therapy (191)
GLP-1 (610)
Government (4408)
Healthcare (18995)
Infectious disease (2674)
Inflammatory bowel disease (113)
Interviews (308)
IPO (16571)
Job creations (3694)
Job search strategy (1428)
Layoffs (439)
Legal (7928)
Lung cancer (174)
Manufacturing (181)
Medical device (13322)
Medtech (13327)
Mergers & acquisitions (19430)
Metabolic disorders (423)
Neuroscience (1564)
NextGen Class of 2024 (6733)
Non-profit (4532)
Northern California (1494)
Obesity (242)
Opinion (198)
Patents (102)
People (57620)
Phase I (20676)
Phase II (29128)
Phase III (21545)
Pipeline (458)
Postmarket research (2590)
Preclinical (8877)
Radiopharmaceuticals (251)
Rare diseases (233)
Real estate (5998)
Regulatory (21955)
Research institute (2403)
Resumes & cover letters (351)
Southern California (1323)
Startups (3746)
United States (13800)
Vaccines (565)
Weight loss (182)
Date
Today (134)
Last 7 days (838)
Last 30 days (3833)
Last 365 days (36669)
2024 (33585)
2023 (41013)
2022 (52276)
2021 (56765)
2020 (54924)
2019 (47419)
2018 (35697)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (731)
Arizona (200)
Asia (38505)
Australia (6402)
California (3407)
Canada (1289)
China (250)
Colorado (146)
Connecticut (160)
Europe (83979)
Florida (458)
Georgia (116)
Illinois (351)
Indiana (198)
Kansas (99)
Maryland (588)
Massachusetts (2710)
Michigan (159)
Minnesota (277)
New Jersey (965)
New York (965)
North Carolina (754)
Northern California (1494)
Ohio (140)
Pennsylvania (847)
South America (1105)
Southern California (1323)
Texas (473)
Utah (92)
Washington State (371)
701,010 Results for "nutcracker therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for mRNA Drug Developers
November 12, 2024
·
3 min read
Biotech Bay
Nutcracker Therapeutics Demonstrates Enhanced Activity of B Cell Lymphoma Candidate NTX-472 at the 2024 ASCO Annual Meeting
Nutcracker Therapeutics, Inc. recently presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
June 5, 2024
·
3 min read
Biotech Bay
Nutcracker Therapeutics to Unveil New Drug Candidate NTX-472 at ASCO 2024 and Participate in the Sachs Oncology Innovation Forum
Nutcracker Therapeutics, Inc. today announced it will introduce its new preclinical drug candidate, NTX-472, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago.
May 16, 2024
·
2 min read
Biotech Bay
Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024
Nutcracker Therapeutics, Inc. today announced that two poster presentations highlighting the company’s RNA therapeutics pipeline will be introduced at the 2024 American Association for Cancer Research (AACR) Annual Meeting.
March 12, 2024
·
2 min read
Biotech Bay
Nutcracker Therapeutics’ Research Partner, the University of California, San Francisco, Presents Foundational Prostate Cancer Data at AAI 2024
Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, detailed data presented by its partners at the University of California, San Francisco on foundational prostate cancer antigen research utilized to inform the development of its mRNA drug candidate, NTX-470.
May 15, 2024
·
4 min read
Drug Development
Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the 2024 AACR Annual Meeting
Nutcracker Therapeutics, Inc recently presented two posters at the American Association for Cancer Research (AACR) Annual Meeting in San Diego: one showcasing the latest preclinical data for the company’s mRNA drug candidate for prostate cancer, NTX-470; and the other highlighting data on the immunomodulatory cytokine, LIGHT.
April 11, 2024
·
4 min read
Business
Nutcracker Therapeutics Named Industry Veteran Samuel Deutsch as Chief Scientific Officer
Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer.
January 8, 2024
·
2 min read
Biotech Bay
Nutcracker Therapeutics to Present Data for Two mRNA Drug Candidates at SITC 2023
Nutcracker Therapeutics, Inc. today announced two poster presentations: one on the company’s lead mRNA therapeutic candidate, NTX-250, which targets human papillomavirus (HPV)-driven cancers; the other on its latest therapeutic candidate, NTX-471, which targets CD47 and CCR4.
October 24, 2023
·
2 min read
Biotech Bay
Nutcracker Therapeutics Demonstrates Anti-tumor Responses of Two Preclinical mRNA Drug Candidates at 2023 SITC Annual Meeting
Nutcracker Therapeutics, Inc. today presented preclinical data for two of its therapeutic candidates: its latest therapeutic candidate, NTX-471, which targets CD47; and the company’s lead mRNA candidate targeting human papillomavirus (HPV)-driven tumors, NTX-250.
November 7, 2023
·
4 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
1 of 70,101
Next
